Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Hironaga Satake; Yu Sunakawa; Yuji Miyamoto; Masato Nakamura; Hiroshi Nakayama; Manabu Shiozawa; Akitaka Makiyama; Kazuma Kobayashi; Yutaro Kubota; Misuzu Mori; Masahito Kotaka; Akinori Takagane; Masahiro Gotoh; Masahiro Takeuchi; Masashi Fujii; Wataru Ichikawa; Takashi Sekikawa

doi:10.18632/oncotarget.25775

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

PDF | How to cite

Oncotarget. 2018; 9:30023-30023. https://doi.org/10.18632/oncotarget.25775

Metrics: PDF 2069 views | ?

Hironaga Satake^1,*, Yu Sunakawa^2,*, Yuji Miyamoto³, Masato Nakamura⁴, Hiroshi Nakayama⁵, Manabu Shiozawa⁶, Akitaka Makiyama⁷, Kazuma Kobayashi⁸, Yutaro Kubota⁹, Misuzu Mori¹⁰, Masahito Kotaka¹¹, Akinori Takagane¹², Masahiro Gotoh¹³, Masahiro Takeuchi¹⁴, Masashi Fujii¹⁵, Wataru Ichikawa¹⁶ and Takashi Sekikawa¹⁶

¹Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan
²Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, 216-8511, Japan
³Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan
⁴Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Nagano, 390-8510, Japan
⁵Department of Surgery, Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan
⁶Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-0815, Japan
⁷Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Kitakyusyu, Fukuoka, 806-8501, Japan
⁸Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan
⁹Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Shinagawa-Ku, Tokyo, 142-8666, Japan
¹⁰Division of Clinical Oncology, Jichi Medical University, Shimotsuke-Shi, Tochigi, 329-0498, Japan
¹¹Gastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, 655-0031, Japan
¹²Department of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Hokkaido, 040-8611, Japan
¹³Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, 569-8686, Japan
¹⁴Department of Clinical Medicine (Biostatistics), Kitasato University School of Pharmacy, Minato-ku, Tokyo, 108-8641, Japan
¹⁵Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan
¹⁵Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, 227-8501, Japan
^*These authors have contributed equally to this work

Published: July 06, 2018

This article has been corrected: The corrected author name is given below:

Wataru Ichikawa

Original article: Oncotarget. 2018; 9:18811-18820. DOI: https://doi.org/10.18632/oncotarget.24702.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25775

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11